1. Alphs L, Nasrallah HA, Bossie C, Fu DJ, Gopal S, Hough D, Turkoz I. Factors associated with relapse in schizophrenia despite adherence to long-acting injectable antipsychotic therapy. Int Clin Psychopharmaco 2016; 31: 202-209.
2.
Anczewska M, Biechowska D, Gałecki P, Janas-Kozik M, Koń B, Skrzypkowska-Brancewicz B, Śremska A, Urbański F, Więckowska B, Zięba M, Kucharska K. Jednostki organizacyjne psychiatrycznej opieki zdrowotnej dla dorosłych – analiza na podstawie danych Narodowego Funduszu Zdrowia z lat 2010–2016. Psychiatr. Pol. 2020; 54: 897-913.
3.
Barnett J, Torous J, Staples P, Sandoval L, Keshavan M, Onnela JP. Relapse prevention in schizophrenia through digital phenotyping: a pilot study. Neuropsychopharmacol 2018; 43: 1660-1666.
4.
Bilikiewicz T. Psychiatria kliniczna. Warszawa, PZWL 1966.
5.
Bleuler E. Lehrbuch der Psychiatrie. Springer, Leipzig 1920.
6.
Bleuler E. Dementia praecox oder Gruppe der Schizophrenien. Leipzig–Wien, Duticke 1911, cyt. wg: New York. Int. Univ. Press. 1950.
7.
Bowtell M, Eaton S, Thien K, Bardell-Williams M, Downey L, Rethseeh A, Killackey E, McGorry P, O’Donoghue B. Rates and predictors of relapse following discontinuation of antipsychotic medication after a first episode of psychosis. Schiz Res 2018; 195: 231-236.
8.
Ceraso A, Lin JJ, Schneider-Thoma J, Siafis S, Tardy M, Komossa K, Heres S, Kissling W, Davis JM, Leucht S. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev 2020. DOI: 10.1002/14651858.CD008016.pub3.
9.
Chanpattana W, Chakrabhand MLS, Sackeim HA, Kitaroonchai W, Kongsakon R, Techakasem P et al. Continuation ECT in treatment-resistant schizophrenia: a controlled study. J ECT 1999; 15: 178-192.
10.
Emsley R, Chiliza B, Asmal L, Harvey HB. The nature of relapse in schizophrenia. BMC Psychiatry. 2013; 13: 50-58.
11.
Gaebel W (red.). Schizophrenia, current science and clinical practice. WEPA, Wiley–Blackwell, Chicheester 2011.
12.
Geabel W, Zielasek J. Schizophrenia in 2020. Trends in diagnosis and therapy. Psychiatry Clin Neurosci 2015; 69: 661-673.
13.
Goldhamer P. Relapse in schizophrenia. Arch Gen Psychiatry 1981; 38: 842-843.
14.
Gumley AI, MacBeth A, Reilly JD, O’Grady M, White RG, McLeod M, Schwannauer Mower KG. Far of recurrence: results of a randomized trial of relapse detection in schizophrenia. Br J Clin Psychol 2015; 54: 49-62.
15.
Isserles M, Remington J, Kaster TS, Daskalakis Z, Blumberger DM. Clinical Effectiveness of Maintenance Electroconvulsive Therapy in Patients with Schizophrenia: A Retrospective Cohort Study. J ECT. 2020; 36: 42-46.
16.
Jarema M (red.). Leczenie farmakologiczne schizofrenii: czynniki biologiczne oraz subiektywne. Bibl Psychiatrii Pol, Kraków 1999.
17.
Jarema M. Psychiatria. W: Gaciong Z, Kardas P (red.), Nieprzestrzegania zaleceń terapeutycznych. Od przyczyn do praktycznych rozwiązań. Naukowa Fundacja Polpharmy, Warszawa 2015; 167-176 (a).
18.
Jarema M (red.). Standardy leczenia farmakologicznego. Via Medica, Gdańsk 2015 (b).
19.
Johnstone EC, Geddes J. How high is the relapse rate in schizophremnia? Acta Psychiatr Scand 1994; suppl. 382: 6-10.
20.
Kristensen D, Bauer J, Hageman I, Jørgensen MB. Electroconvulsive therapy for treating schizophrenia: a chart review of patients from two catchment areas. Eur Arch Psychiatry Clin Neurosci 2011; 261: 425-432.
21.
Lader M. Pharmacological prevention of relapse. Kaoshing J Med. Sci 1998; 14: 448-457.
22.
Lauriello J. Prevalence and impact of relapse in patients with schizophrenia. Clin Psychiatry 2020; 81. DOI: 10.4088/JCP.MS19053BR1C.
23.
Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Davis JM. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev 2012. DOI: 10.1002/14651858.CD008016.pub2.
24.
Ohmori T, Kouichi I, Tomohiro A. Psychotic relapse and maintenance therapy in paranoid schizophrenia: a 15 year follow up. Eur Arch Psychiatry Clin Neurosci 1999, 249: 73-78.
25.
Porcelli S, Bianchini O, De Girolamo G, Aguiglia E, Crea L, Serretti A. Clinical factors related to schizophrenia relapse. Int J Psychiatry Clin Pract 2014; 20: 54-69.
26.
Remington G, Foussias G, Agid O, Fervaha G, Takeuchi H, Hahn M. The neurobiology of relapse in schizophrenia. Schiz Res 2014; 152: 381-390.
27.
Saito Y, Sakurai H, Kane JM, Schooler N, Suzuki T, Mimura M, Uchida H. Predicting relapse with residua symptoms in schizophrenia: a secondary analysis of the PROACTIVE trial. Schiz Res. 2020; 215: 173-180.
28.
Shelef A, Mazeh D, Berger U, Baruch Y, Barak Y. Acute electroconvulsive therapy followed by maintenance electroconvulsive therapy decreases hospital re-admission rates of older patients with severe mental illness. J ECT. 2015; 31: 125-128.
29.
Sherin JE, Marder SR. Pharmacological treatment. W: Geabel W (red). Schizophrenia, current science and clinical practice. Wiley–Blackwell, Chichester 2011; s. 166.
30.
Smith T, Weston C, Lieberman J. Schizophrenia maintenance treatment. Am Fam Phys 2010; 82: 338-339.
31.
Taylor D, Paton C, Kapur S. Prescribing guidelines in psychiatry. Wiley–Blackwell 2012.
32.
Ward HB, Szabo ST, Rakesh G. Maintenance ECT in schizophrenia: a systematic review. Psychiatry Res 2018; 264: 131-142.
33.
Yang Y, Cheng X, Xu Q, Li R, Liu Z, Wang L. The maintenance of modified electroconvulsive therapy combined with risperidone is better than risperidone alone in preventing relapse of schizophrenia and improving cognitive function. Arq Neuropsiquiatr 2016; 74: 823-828.
